Tulane University COVID Antibody and Immunity Network (TUCAIN)
Tulane University COVID Antibody and Immunity Network (TUCAIN)
批准号:
10706732
负责人:
JAMES E Robinson
金额:
$43.99万
依托单位国家:
美国
项目类别:
财政年份:
2020
资助国家:
美国
项目状态:
未结题
起止时间:
2020-09-30 至 2025-08-31
关键词:
2019-nCoVAddressAdvanced DevelopmentAlgorithmsAntibodiesAntibody ResponseAntibody-mediated protectionApplied ResearchBig DataBloodBlood specimenCOVID-19COVID-19 patientCOVID-19 survivorsCOVID-19 treatmentCellular ImmunityCenters for Disease Control and Prevention (U.S.)ClinicalClinical DataCollectionDataData SetDevelopmentDiagnosisDiseaseEvolutionFundingGoalsHumoral ImmunitiesImmune responseImmunityImmunocompromised HostImmunologicsIndividualInfectionKnowledgeLongevityLouisianaMalignant NeoplasmsMeasuresMedicineMemoryMethodsMissionPathogenesisPathogenicityPatient-Focused OutcomesPatientsPersonsPlasmaRecurrenceReportingResearchRiskSARS-CoV-2 immunitySerology testSerumSpecial PopulationSurvivorsSystems BiologyTechnologyTherapeuticTimeUniversitiesVaccinesViralViral Hemorrhagic FeversVirusbasebiobankcell mediated immune responsecohortconvalescent plasmacoronavirus diseasehuman pathogenimprovedinsightlongitudinal analysismortalityneutralizing antibodynovelpersonalized medicinepreventprogramspublic health emergencyresponsescreeningtherapeutic evaluationtreatment strategy
中文摘要
点击翻译按钮获取中文摘要
英文摘要
CD4+ T cells and B cells are critical to generate high-affinity antibodies against most pathogens, and antigen-presenting cells such as dendritic cells and macrophage are essential in delivering antigen to the lymph nodes to generate long-lived cellular and humoral immunity. As immunocompromised individuals often have deficiencies or abnormalities in one or more immune cell populations, we hypothesize that analysis of immunocompromised patients with deficiencies/abnormalities in distinct cellular compartments (eg. plasma cells in multiple myeloma; CD4+ T cells in people living with HIV; lymphocytes in chronic lymphocytic leukemia) will be able to define the role of a given immune cell type on generation of durable protective immunity against SARS-CoV-2. Moreover, these comparative analyses may further identify specific gaps in SARS-CoV-2 immunity within different immunocompromised populations that may be complemented with therapies. Through our funded U54 parent grant, we have established several cohorts of immunocompromised populations, including people living with HIV and patients with various hematologic and solid tumor cancer malignancies. In addition, we have developed a comprehensive immune analysis platform that integrates measures of cellular and humoral immunity that will allow us to perform comparative analyses of cellular and humoral immunity across multiple immunocompromised patient populations.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Admin-Core-001
-
批准号:10709113
-
项目类别:
-
资助金额:$43.99万
-
财政年份:2022
-
负责人:JAMES E Robinson
-
依托单位:
Longitudinal Analyses of Antibody Responses to SARS-CoV-2
-
批准号:10222403
-
项目类别:
-
资助金额:$86.02万
-
财政年份:2020
-
负责人:JAMES E Robinson
-
依托单位:
Tulane University COVID Antibody and Immunity Network (TUCAIN)
-
批准号:10222399
-
项目类别:
-
资助金额:$374.32万
-
财政年份:2020
-
负责人:JAMES E Robinson
-
依托单位:
Tulane University COVID Antibody and Immunity Network (TUCAIN)
-
批准号:10688376
-
项目类别:
-
资助金额:$192.04万
-
财政年份:2020
-
负责人:JAMES E Robinson
-
依托单位:
Longitudinal Analyses of Antibody Responses to SARS-CoV-2
-
批准号:10688391
-
项目类别:
-
资助金额:$51.01万
-
财政年份:2020
-
负责人:JAMES E Robinson
-
依托单位:
Coronavirus Immunoassay Core
-
批准号:10222402
-
项目类别:
-
资助金额:$45.62万
-
财政年份:2020
-
负责人:JAMES E Robinson
-
依托单位:
Tulane University COVID Antibody and Immunity Network (TUCAIN)
-
批准号:10855027
-
项目类别:
-
资助金额:$279.23万
-
财政年份:2020
-
负责人:JAMES E Robinson
-
依托单位:
Coronavirus Immunoassay Core
-
批准号:10688390
-
项目类别:
-
资助金额:$37.3万
-
财政年份:2020
-
负责人:JAMES E Robinson
-
依托单位:
Human and monkey Mabs to Quaternary Epitopes
-
批准号:7904634
-
项目类别:
-
资助金额:$42.59万
-
财政年份:2010
-
负责人:JAMES E Robinson
-
依托单位:
HIV-1 gp120-Conjugate Vaccines
-
批准号:6799602
-
项目类别:
-
资助金额:$22.28万
-
财政年份:2003
-
负责人:JAMES E Robinson
-
依托单位:
HIV-1 gp120-Conjugate Vaccines
-
批准号:6655474
-
项目类别:
-
资助金额:$22.28万
-
财政年份:2003
-
负责人:JAMES E Robinson
-
依托单位:
RHESUS MABS FROM SHIV INFECTED MACAQUES
-
批准号:6020278
-
项目类别:
-
资助金额:$22.27万
-
财政年份:1999
-
负责人:JAMES E Robinson
-
依托单位:
RHESUS MABS FROM SHIV INFECTED MACAQUES
-
批准号:6632049
-
项目类别:
-
资助金额:$24.11万
-
财政年份:1999
-
负责人:JAMES E Robinson
-
依托单位:
RHESUS MABS FROM SHIV INFECTED MACAQUES
-
批准号:6170917
-
项目类别:
-
资助金额:$22.06万
-
财政年份:1999
-
负责人:JAMES E Robinson
-
依托单位:
RHESUS MABS FROM SHIV INFECTED MACAQUES
-
批准号:6374302
-
项目类别:
-
资助金额:$22.72万
-
财政年份:1999
-
负责人:JAMES E Robinson
-
依托单位:
RHESUS MABS FROM SHIV INFECTED MACAQUES
-
批准号:6510920
-
项目类别:
-
资助金额:$23.4万
-
财政年份:1999
-
负责人:JAMES E Robinson
-
依托单位:
ACTG--COMPARATIVE TRIALS OF ZDV VS D4T IN CHILDREN WITH HIV INFECTION
-
批准号:6253660
-
项目类别:
-
资助金额:$1.98万
-
财政年份:1997
-
负责人:JAMES E Robinson
-
依托单位:
SAFETY AND TOLERANCE OF CHRONIC NEVIRAPINE DOSING IN HIV 1 INFECTED CHILDREN
-
批准号:6253659
-
项目类别:
-
资助金额:$1.98万
-
财政年份:1997
-
负责人:JAMES E Robinson
-
依托单位:
ACTG--PHARMACOKINETICS/SAFETY AND TOLERANCE OF NEVIRAPINE
-
批准号:6253657
-
项目类别:
-
资助金额:$1.98万
-
财政年份:1997
-
负责人:JAMES E Robinson
-
依托单位:
ACTG--COMBINED ZIDOVUDINE-LAMIVUDINE (3TC) VS DDI MONOTHERAPY
-
批准号:6253680
-
项目类别:
-
资助金额:$1.98万
-
财政年份:1997
-
负责人:JAMES E Robinson
-
依托单位:
海外基金